Evaluation of the preoperative neutrophil-to-lymphocyte ratio as a predictor of the micropapillary component of stage IA lung adenocarcinoma

  • 0Department of Cardiothoracic Surgery, Zhoushan Hospital, Zhejiang, P.R. China.

|

|

Summary

This summary is machine-generated.

The preoperative neutrophil-to-lymphocyte ratio can identify the micropapillary component in stage IA lung adenocarcinoma. This inflammation marker did not predict recurrence, suggesting its potential role in surgical strategy optimization.

Area Of Science

  • Oncology
  • Pathology
  • Inflammation Markers

Background

  • Lung adenocarcinoma is the most common type of lung cancer.
  • Stage IA lung adenocarcinoma has a generally good prognosis, but certain histologic subtypes may influence outcomes.
  • Identifying specific tumor components and their predictors is crucial for treatment planning.

Purpose Of The Study

  • To evaluate if inflammation markers can identify solid or micropapillary components in stage IA lung adenocarcinoma.
  • To determine the prognostic impact of these components and inflammation markers on recurrence.

Main Methods

  • Retrospective analysis of 654 patients with stage IA lung adenocarcinoma (2013-2019).
  • Logistic regression to identify predictors of solid and micropapillary components.
  • Evaluation of inflammation markers (e.g., neutrophil-to-lymphocyte ratio) and recurrence relationship.

Main Results

  • High preoperative neutrophil-to-lymphocyte ratio was associated with the micropapillary component.
  • No significant difference in systemic inflammation markers between solid and non-solid components.
  • Preoperative neutrophil-to-lymphocyte ratio, tumor size, and CEA independently predicted the micropapillary component.
  • No correlation found between systemic inflammation markers and stage IA lung adenocarcinoma recurrence.

Conclusions

  • Preoperative neutrophil-to-lymphocyte ratio is an independent predictor of the micropapillary component in stage IA lung adenocarcinoma.
  • Further research is warranted on using this ratio to optimize surgical strategies for stage IA lung adenocarcinoma.